The Iceman Trial: Randomized Comparison of Mohs, Staged Excision, and Wide Excision for Early-Stage Melanoma

Conclusions

• Current guidelines still do not recommend Mohs micrographic surgery for primary treatment of invasive cutaneous melanoma when standard clinical margins can be obtained, but they allow selective use for melanoma in situ and anatomically constrained sites.
• The evidence base for Mohs and staged excision in melanoma is largely retrospective, with no prospective comparisons to standard excision, so claims of superiority remain unproven.
• Reported survival advantages for Mohs over wide excision likely reflect selection bias and confounding rather than a true biological treatment effect, because the compared patient groups are not equivalent.
• There is a strong rationale to study whether complete margin control improves local recurrence outcomes, but the key unanswered question is whether it is actually better than standard wide excision in appropriately selected early melanomas.
• The ICEMAN trial is designed to provide the first randomized evidence comparing narrow excision or complete margin control with standard wide excision in low-risk stage I melanoma.
• By using the Merlin CP-GEP test to select lower-risk patients, the trial also aims to test whether sentinel lymph node biopsy can be safely omitted in this group.
• If successful, the study could establish whether some early melanomas can be treated safely with smaller-than-standard margins without worsening recurrence or survival outcomes.
• The most important outcome the field is waiting for is whether localized melanoma can be managed with less extensive surgery while preserving local control, quality of life, and complication rates.